Gilead Sciences: Innovations in Oncology & Cellular Therapy Along With Anti-Viral Focus! 

Gilead Sciences Inc. showcased a solid performance for the second quarter of 2024, marked by robust commercial execution and growth across key therapeutic areas such as HIV, liver diseases, and oncology. Notably, Biktarvy, an HIV treatment, observed an 8% year-over-year growth, while Trodelvy in oncology saw a 23% increase, and cell therapy revenues increased by 11%. Additionally, the company reported disciplined management of operating expenses which significantly contributed to bottom-line growth.